Literature DB >> 35948005

A reverse genetics and genomics approach to gene paralog function and disease: Myokymia and the juxtaparanode.

Dana Marafi1, Nina Kozar2, Ruizhi Duan3, Stephen Bradley2, Kenji Yokochi4, Fuad Al Mutairi5, Nebal Waill Saadi6, Sandra Whalen7, Theresa Brunet8, Urania Kotzaeridou9, Daniela Choukair10, Boris Keren11, Caroline Nava11, Mitsuhiro Kato12, Hiroshi Arai13, Tawfiq Froukh14, Eissa Ali Faqeih15, Ali M AlAsmari15, Mohammed M Saleh15, Filippo Pinto E Vairo16, Pavel N Pichurin17, Eric W Klee18, Christopher T Schmitz19, Christopher M Grochowski3, Tadahiro Mitani3, Isabella Herman20, Daniel G Calame20, Jawid M Fatih3, Haowei Du3, Zeynep Coban-Akdemir21, Davut Pehlivan20, Shalini N Jhangiani22, Richard A Gibbs23, Satoko Miyatake24, Naomichi Matsumoto25, Laura J Wagstaff26, Jennifer E Posey3, James R Lupski27, Dies Meijer28, Matias Wagner29.   

Abstract

The leucine-rich glioma-inactivated (LGI) family consists of four highly conserved paralogous genes, LGI1-4, that are highly expressed in mammalian central and/or peripheral nervous systems. LGI1 antibodies are detected in subjects with autoimmune limbic encephalitis and peripheral nerve hyperexcitability syndromes (PNHSs) such as Isaacs and Morvan syndromes. Pathogenic variations of LGI1 and LGI4 are associated with neurological disorders as disease traits including familial temporal lobe epilepsy and neurogenic arthrogryposis multiplex congenita 1 with myelin defects, respectively. No human disease has been reported associated with either LGI2 or LGI3. We implemented exome sequencing and family-based genomics to identify individuals with deleterious variants in LGI3 and utilized GeneMatcher to connect practitioners and researchers worldwide to investigate the clinical and electrophysiological phenotype in affected subjects. We also generated Lgi3-null mice and performed peripheral nerve dissection and immunohistochemistry to examine the juxtaparanode LGI3 microarchitecture. As a result, we identified 16 individuals from eight unrelated families with loss-of-function (LoF) bi-allelic variants in LGI3. Deep phenotypic characterization showed LGI3 LoF causes a potentially clinically recognizable PNHS trait characterized by global developmental delay, intellectual disability, distal deformities with diminished reflexes, visible facial myokymia, and distinctive electromyographic features suggestive of motor nerve instability. Lgi3-null mice showed reduced and mis-localized Kv1 channel complexes in myelinated peripheral axons. Our data demonstrate bi-allelic LoF variants in LGI3 cause a clinically distinguishable disease trait of PNHS, most likely caused by disturbed Kv1 channel distribution in the absence of LGI3.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  KCNA; LGI3; bi-allelic variation; facial myokymia; gene and genome instability; genomic rearrangement; multi-exonic CNV; neurobiology of disease; peripheral nerve hyperexcitability syndromes; potassium channel complexes

Mesh:

Substances:

Year:  2022        PMID: 35948005      PMCID: PMC9502070          DOI: 10.1016/j.ajhg.2022.07.006

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.043


  44 in total

1.  SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data.

Authors:  Maximilian Diehn; Gavin Sherlock; Gail Binkley; Heng Jin; John C Matese; Tina Hernandez-Boussard; Christian A Rees; J Michael Cherry; David Botstein; Patrick O Brown; Ash A Alizadeh
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

2.  Developmental changes in KCNQ2 and KCNQ3 expression in human brain: possible contribution to the age-dependent etiology of benign familial neonatal convulsions.

Authors:  Takeshi Kanaumi; Sachio Takashima; Hiroshi Iwasaki; Masayuki Itoh; Akihisa Mitsudome; Shinichi Hirose
Journal:  Brain Dev       Date:  2007-12-31       Impact factor: 1.961

3.  Serum of Isaacs' syndrome suppresses potassium channels in PC-12 cell lines.

Authors:  Y Sonoda; K Arimura; A Kurono; M Suehara; M Kameyama; S Minato; A Hayashi; M Osame
Journal:  Muscle Nerve       Date:  1996-11       Impact factor: 3.217

Review 4.  Peripheral Nerve Hyperexcitability Syndromes.

Authors:  Komal Sawlani; Bashar Katirji
Journal:  Continuum (Minneap Minn)       Date:  2017-10

5.  Facial myokymia.

Authors:  E W Radü; V Skorpil; H E Kaeser
Journal:  Eur Neurol       Date:  1975       Impact factor: 1.710

6.  Next Generation Sequencing and Genome-Wide Genotyping Identify the Genetic Causes of Intellectual Disability in Ten Consanguineous Families from Jordan.

Authors:  Tawfiq Jamal Froukh
Journal:  Tohoku J Exp Med       Date:  2017-12       Impact factor: 1.848

7.  Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy.

Authors:  José M Morante-Redolat; Ana Gorostidi-Pagola; Salomé Piquer-Sirerol; Amets Sáenz; Juan J Poza; Juan Galán; Stefan Gesk; Theologia Sarafidou; Victor-F Mautner; Simona Binelli; Eike Staub; Bernd Hinzmann; Lisa French; Jean-F Prud'homme; Daniela Passarelli; Paolo Scannapieco; Carlo A Tassinari; Giuliano Avanzini; José F Martí-Massó; Lan Kluwe; Panagiotis Deloukas; Nicholas K Moschonas; Roberto Michelucci; Reiner Siebert; Carlo Nobile; Jordi Pérez-Tur; Adolfo López de Munain
Journal:  Hum Mol Genet       Date:  2002-05-01       Impact factor: 6.150

8.  LGI1 mutations in autosomal dominant partial epilepsy with auditory features.

Authors:  R Ottman; M R Winawer; S Kalachikov; C Barker-Cummings; T C Gilliam; T A Pedley; W A Hauser
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

9.  Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves.

Authors:  P Shillito; P C Molenaar; A Vincent; K Leys; W Zheng; R J van den Berg; J J Plomp; G T van Kempen; G Chauplannaz; A R Wintzen
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

Review 10.  Autoimmune encephalitis: clinical spectrum and management.

Authors:  Christopher E Uy; Sophie Binks; Sarosh R Irani
Journal:  Pract Neurol       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.